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ABSTRACT
The UK Refractory Asthma Stratiﬁcation Programme
(RASP-UK) will explore novel biomarker stratiﬁcation
strategies in severe asthma to improve clinical
management and accelerate development of new
therapies. Prior asthma mechanistic studies have not
stratiﬁed on inﬂammatory phenotype and the
understanding of pathophysiological mechanisms in
asthma without Type 2 cytokine inﬂammation is limited.
RASP-UK will objectively assess adherence to
corticosteroids (CS) and examine a novel composite
biomarker strategy to optimise CS dose; this will also
address what proportion of patients with severe asthma
have persistent symptoms without eosinophilic airways
inﬂammation after progressive CS withdrawal. There will
be interactive partnership with the pharmaceutical
industry to facilitate access to stratiﬁed populations for
novel therapeutic studies.
INTRODUCTION
The Medical Research Council has recently funded
an ambitious stratiﬁed medicines programme in
severe asthma (the UK Refractory Asthma
Stratiﬁcation Programme (RASP-UK http://www.
rasp.org.uk/). In asthma, disease stratiﬁcation has
traditionally followed a ‘one-size ﬁts all’ approach,
based on level of asthma control and response to
‘stepwise’ increases in corticosteroid (CS) treat-
ment. More recently, stratiﬁcation has been based
on inﬂammatory biomarkers, with sputum analysis
and transcriptomic proﬁling demonstrating that
∼50% of patients with asthma have typical eosino-
philic airway inﬂammation driven by ‘Type 2’ cyto-
kines (T2 cytokines: interleukin (IL)-4, IL-5,
IL-13); this T2-high asthma has been shown to
respond well to CS therapy. In the remainder of
patients, there is limited evidence for a major role
for T2 cytokines and this has been termed ‘T2-low
asthma’, where patients show little or no response
to CS therapy.1 There is also evidence of signiﬁcant
disease heterogeneity in severe asthma, with only
25%–50% of patients having the prototypic T2
gene signature consistent with T2-high disease. In
many cases of severe asthma, it therefore seems
likely that the CS dose has been escalated inappro-
priately to try and manage persistent symptoms
that are not CS responsive. Given the clear evi-
dence that CS responsiveness is conﬁned to
T2-high disease, the cornerstone of the RASP-UK
stratiﬁcation programme is around failure of
response to CS therapy in severe asthma.
We propose that in patients with severe asthma,
failure to respond to high-dose CS treatment
occurs for three principal reasons:
1. Non-adherence to CS treatment.
2. Impaired CS responsiveness—in some patients,
despite adherence with high-dose inhaled CS,
there is persistent T2-high inﬂammation/eosino-
philia and these patients frequently require sys-
temic CS to achieve an acceptable level of
disease control.
3. Non-responsiveness to CS in patients with
T2-low asthma—we believe that CS will have
been escalated inappropriately in this group in
clinical practice.
NON-ADHERENCE TO CS TREATMENT
Non-adherence to inhaled CS and oral CS therapy
is a major clinical problem, present in 30%–50% of
patients with difﬁcult-to-control asthma. Non-
adherence can be intentional or non-intentional, is
poorly detected by physicians and asthma nurses
and is associated with poor asthma outcomes and
increased healthcare costs.2 Moreover, enrolment
of non-adherent patients into clinical trials is
believed to contribute to the frequently observed
improvement in placebo arms of asthma clinical
trials, complicating the interpretation of trial results
and reducing statistical power. Importantly, expen-
sive new biological therapies targeting T2-high
patients can potentially be used inappropriately in
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patients who would often be controlled with improved adher-
ence to inhaled CS. Patients with difﬁcult-to-control asthma and
fractional exhaled nitric oxide (FeNO) >45 ppb have a high risk
of exacerbation3 and the key clinical question is whether failure
to control their disease is because of non-adherence to inhaled
CS treatment or whether they have relative CS-resistant T2-high
asthma and, thus, require additional treatment with drugs that
target T2 mechanisms (eg, anti-IL-5 and anti-IL-13 treatments).
RASP-UK will therefore use biomarker-based assessments of
inhaled CS exposure and response in biomarker-high patients
(‘FeNO suppression test’—reference 4 online supplementary
data) using remote monitoring technologies to deﬁne CS
responsivity and thus optimise inhaled CS where appropriate.
IMPAIRED CS RESPONSIVENESS
In some patients with severe asthma, despite adherence with
high-dose inhaled CS, there is persistent T2-high inﬂammation
and airway eosinophilia and these patients frequently require
systemic CS to achieve disease control. The availability of many
new biological therapies targeting T2-high disease in the next
5 years will generate many interesting questions, including dif-
ferential efﬁcacy between monoclonal antibodies targeting IL-5/
IL-5R (mepolizumab, bendralizumab, relizumab), IL-13 (lebriki-
zumab, tralokinumab) and IL-4Rα (dupilumab). Other strategies
targeting the T2-axis, including anti-CrTh2 and novel anti-IgE
therapies (quilizumab, Medi-4212, QGE031), will also be tar-
geting overlapping patient groups; identifying which patients
respond better to different classes of drugs may require
‘head-to-head’ studies. Many of these new therapies are
expected to come to market with a companion diagnostic or
predictive biomarker(s) of clinical response.
NON-RESPONSIVENESS TO CS
Inhaled CS remain the mainstay of asthma treatment, controlling
disease through suppression of T2/eosinophilic inﬂammation in
the airway. However, not all symptoms in severe asthma respond
to CS, and CS responsiveness is minimal in the absence of T2
inﬂammation.1 Therefore, new algorithms for guiding CS treat-
ment in patients with severe asthma are needed, which are not
solely based on clinical symptoms and lung function and which
can be delivered in the clinic. Titrating CS against sputum eosino-
philia improves asthma control by reducing asthma exacerba-
tions4 but this strategy is difﬁcult to deliver in real-world clinical
settings. FeNO is straightforward to measure, but when used as a
single biomarker, it has been disappointing in titrating CS in
patients with moderate asthma.5 Periostin is a secreted matricellu-
lar protein from a number of tissues including airway epithelial
cells and is upregulated by T2 cytokines (IL-4 and IL-13) and is
associated with airway eosinophilia in patients with severe
asthma.1 An assay for serum periostin is being developed to help
identify a periostin-high responder population for the anti-IL-13
monoclonal antibody lebrikizumab.
We have previously examined the predictive value of FeNO,
blood eosinophils and serum periostin as a composite biomarker
to predict exacerbation risk in the placebo arms of clinical trials
with lebrikizumab and omalizumab in patients taking at least
500 μg ﬂuticasone propionate and a second controller (see
online supplementary data). This analysis has demonstrated
that, individually, these biomarkers are all correlated with
exacerbation risk, but using the three biomarkers in a ‘compos-
ite’ scoring system further differentiated subjects on the basis of
exacerbation rate (see online supplementary ﬁgure E1). This
predictive composite score is independent of asthma symptoms
(measured by asthma control questionnaire) and lung function
(see online supplementary ﬁgures E2 and E3) which current
asthma guidelines advocate for treatment adjustment.
RASP-UK will therefore use this scoring system to adjust CS
treatment in a randomised, pragmatic, multicentre, parallel
group trial in patients with severe asthma and baseline FeNO
<45 ppb comparing standard care with treatment guided by
composite biomarkers (as discussed above, patients with FeNO
≥45 ppb have a high risk of exacerbation and are not candidates
for CS reduction). Exploratory outcomes will examine the prog-
nostic value of selected, novel blood and urine biomarkers from
the Unbiased BIOmarkers in PREDiction of respiratory disease
outcomes (U-BIOPRED) programme for exacerbation risk
(http://www.europeanlung.org/en/projects-and-research/projects/
u-biopred/home). The programme will also characterise the
inﬂammatory and microbiomic proﬁles (viral, bacterial, fungal)
in exacerbations in both study arms.
One of the anticipated outcomes of this biomarker-based
stratiﬁcation will be identiﬁcation of a patient group with
T2-low severe asthma who have persistent symptoms and
exacerbations which are not CS responsive and in whom T2
inﬂammation biomarkers (eosinophils, FeNO, periostin) are
adequately controlled with moderate doses of inhaled CS. We
know that this patient group exists based on data from a com-
parable sputum stratiﬁcation study where one-third of patients
had a sputum eosinophil count of <1.9% when repeatedly mea-
sured over 12 months despite steroid withdrawal.4 There are
currently few treatment options for these patients representing a
signiﬁcant unmet medical need where new targets need to be
identiﬁed so drugs can be developed. One of the core aims of
RASP-UK is to characterise this group in detail to deﬁne import-
ant structure/function/symptom relationships. This will include
transcriptomic and microbiomic proﬁling compared with age
and gender matched patients with refractory eosinophilic
asthma and stable asthma controlled with low-dose inhaled CS.
These groups will be followed up for 12 months to identify
their exacerbation pattern and stability of the phenotype.
Previous research has focused on eosinophilia as a prognostic
for exacerbation, but ‘non-eosinophilic cohorts’ also experience
exacerbations and potent anti-eosinophilic therapies have not
eradicated severe exacerbations in clinical trials. A better under-
standing of the mechanism and phenotype of exacerbations in
this T2-low cohort is fundamental to targeting exacerbations in
this group.
CONCLUSION
RASP-UK is a logical, clinically focused, stratiﬁcation pro-
gramme which will develop a clinical model to assess and
phenotype patients with severe asthma (ﬁgure 1). It will identify
appropriate patients for novel biological treatments that target
the T2-cytokine axis (T2 biomarker high when adherent to high
dose inhaled CS), will optimise CS treatment so that excessive
CS exposure does not cause unnecessary morbidity and will
facilitate a research focus and better understanding in a major
area of ‘unmet need’, speciﬁcally non-T2/non-CS responsive
severe asthma. Harmonised protocols for patient phenotyping
will also allow stratiﬁed patient groups to enter proof of
concept clinical trials which target the biology of their disease
rather than using the usual broad inclusion criteria, where many
of the patients are unlikely to respond; this will streamline and
reduce size for early drug development in severe asthma. The
RASP-UK Consortium vision is to effect a paradigm shift in
asthma care through a logical stratiﬁed approach to severe
asthma and to establish a long-term collaborative infrastructure
for translational research excellence in the UK.
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Figure 1 Flow diagram for the RASP-UK Clinical Stratiﬁcation Programme. ATS, American Thoracic Society; ERS, European Respiratory Society;
FeNO, fractional exhaled nitric oxide; FP, Fluticasone Propionate; RASP-UK, UK Refractory Asthma Stratiﬁcation Programme.
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